# US 2004/0081982 A1 · Neocentromere-based mini-chromosomes or artificial chromosomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081982 A1
- Document ID: US20040081982A1
- Status: Published application
- Kind: A1
- Application number: 10/463,981
- Filed: 2003-06-17
- Published: 2004-04-29
- Earliest claimed: 2000-12-21
- Inventors: Kong-Hong Andy Choo; Lee Hwa Wong; Richard Eric Saffrey
- Web page: https://patentgrep.com/patent/US20040081982A1

## CPC

- C12N 15/68: Stabilisation of the vector
- C12N 15/85: for animal cells
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2800/204: of bacterial origin, e.g. BAC
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed generally to a defined or isolated nucleic acid molecule encompassing a neocentreomere or a functional derivative thereof or a latent, synthetic or hybrid form thereof and its use inter alia in developing a range of eukaryotic mini-chromosomes and artificial chromosomes including mammalian (e.g. human) and non-mammalian mini-chromosomes and artificial chromosomes. The present invention further provides a telomere-associated chromosome truncation (TACT) approach to develop mini-chromosomes, but is not limited to this approach. It is directed to any truncation approach that produces a neocentromere-containing mini-chromosome, or any transfection approach using cloned or pre-fabricated DNA that provides neocentromere function in the construction of artificial chromosome. Such mini-chromosomes and artificial chromosomes are useful in a range of genetic therapies.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a sequence of nucleotides derived from a eukaryotic chromosome and encompassing a neocentromere, which nucleic acid molecule exists in a truncated form in a compatible cell or, when introduced by transfection as a pre-fabricated DNA entity into a compatible cell, is capable of replicating, acting as an extra chromosomal element, and segregating with cell division.

### Claim 2 (depends on 1)

The isolated nucleic acid molecule of claim 1 wherein the eukaryotic chromosome is derived from a mammal, including a human or primate, a plant, an avian species, an insect, a worm, a fungus, a yeast or a reptile.

### Claim 3 (depends on 2)

The isolated nucleic acid molecule of claim 2 wherein the eukaryotic chromosome is derived from a human.

### Claim 4 (depends on 2)

The isolated nucleic acid molecule of claim 2 wherein the eukaryotic chromosome is derived from a livestock animal.

### Claim 5 (depends on 1)

The isolated nucleic acid of claim 1 comprising a q′ arm of the mardel(10) chromosome or its equivalent truncated by targeted telomere-associated truncation and further comprising the p′ arm of the mardel(10) chromosome or its equivalent truncated by random truncation.

### Claim 6 (depends on 5)

The isolated nucleic acid molecule of claim 5 wherein said nucleic acid molecule comprises a neocentromere at a location equivalent to between q24 and q26 on chromosome 10 or its equivalent.

### Claim 7 (depends on 6)

The isolated nucleic acid molecule of claim 6 wherein said nucleic acid molecule comprises a neocentromere at a location equivalent to at or about q25 on chromosome 10 or its equivalent.

### Claim 8 (depends on 7)

The isolated nucleic acid molecule of claim 7 wherein said nucleic acid molecule comprises a neocentromere at a location equivalent to at or about q25.2 on chromosome 10 or its equivalent.

### Claim 9 (depends on 1, 6, 7, 8)

The nucleic acid molecule of any one of claims 1, 6, 7 or 8 wherein the region corresponding to a neocentromere is substantially devoid of α-satellite DNA.

### Claim 10 (depends on 9)

The nucleic acid molecule of claim 9 wherein the nucleic acid molecule is from about 0.5 to about 2.0 Mb in size.

### Claim 11 (depends on 10)

The nucleic acid molecule of claim 10 wherein the nucleic acid molecule is from about 0.8 to about 1.6 Mb in size.

### Claim 12

A method for identifying a neocentromere or a functional homolog thereof, said method comprising isolating DNA by chromatin immunoprecipitation with an antibody specific to mammalian CENP-A and/or CENP-C or an antibody capable of cross interacting with mammalian CENP-A and/or CENP-C, amplifying the DNA isolated by immunoprecipitation, incorporating a label into the amplified DNA, probing a DNA array comprising genomic DNA or its equivalent with the labeled, amplified DNA, and identifying and isolating clones which hybridize to said immunoprecipitated DNA.

### Claim 13 (depends on 12)

The method of claim 12 wherein the mammal is a human, livestock animal, companion animal or laboratory test animal.

### Claim 14 (depends on 13)

The method of claim 13 wherein the mammal is a human.

### Claim 15 (depends on 14)

The method of claim 14 wherein the neocentromere is at a location equivalent to between p24 and p26 on chromosome 10 or its equivalent.

### Claim 16 (depends on 15)

The method of claim 15 wherein the neocentromere is at a location at or about q25 on chromosome 10 or its equivalent.

### Claim 17 (depends on 16)

The method of claim 16 wherein the neocentromere is at a location at or about q25.2 on chromosome 10 or its equivalent.

### Claim 18

An isolated human neocentromere-based mini-chromosome (NC-MiC), said NC-MiC comprising a neocentromere or a latent, synthetic or hybrid form thereof which enables stable segregation during cell division.

### Claim 19 (depends on 18)

The isolated mini-chromosome of claim 18 comprising a q′ arm of the mardel(10) chromosome or its equivalent truncated by targeted telomere-associated truncation and further comprising the p′ arm of the mardel(10) chromosome or its equivalent truncated by random truncation.

### Claim 20 (depends on 19)

The isolated mini-chromosome of claim 19 wherein the neocentromere is at a location equivalent to between q24 and q26 on chromosome 10 or its equivalent.

### Claim 21 (depends on 20)

The isolated mini-chromosome of claim 20 wherein the neocentromere is at a location at or about q25 on chromosome 10 or its equivalent.

### Claim 22 (depends on 20)

The isolated mini-chromosome of claim 20 wherein the neocentromere is at a location at or about q25.2 on chromosome 10 or its equivalent.

### Claim 23

A method for generating a mini-chromosome, said method comprising:
introducing into a human or mammalian cell which carries a chromosome containing a neocentromere, a truncation construct comprising a vector having telomeric sequences, a selectable marker, homologous targeting DNA on one or other of the q′ or p′ arm of the target chromosome;
selecting for cells expressing the selectable marker;
introducing into said cells a second truncation construct comprising the other of said q′ or p′ targeting DNA;
selecting for cells expressing the selectable marker associated with said second truncation construct; and
then isolating the truncated chromosome which comprises a neocentromere.

### Claim 24 (depends on 23)

The method of claim 23 wherein the cell is a human cell.

### Claim 25 (depends on 24)

The method of claim 24 wherein the neocentromere is at a location equivalent to between q24 and q26 on chromosome 10 or its equivalent.

### Claim 26 (depends on 24)

The method of claim 24 wherein the neocentromere is at a location at or about q25 on chromosome 10 or its equivalent.

### Claim 27 (depends on 24)

The method of claim 24 wherein the neocentromere is at a location at or about q25.2 on chromosome 10 or its equivalent.

### Claim 28

An isolated cell comprising a chromosome having q′ and p′ arms flanking a neocentromere wherein one or both q′ and/or p′ arms are truncated.

### Claim 29

An isolated cell line deposited at ECAAC under Accession 00122001 (CHO/BE ZB30).

### Claim 30

An isolated cell line deposited at ECAAC under Accession 00122002 (HT1080-MIC 1).

### Claim 31

An isolated cell line deposited at ECAAC under Accession 00122003 (HT1080-MIC 2).

### Claim 32

An isolated cell line deposited at ECAAC under Accession 00122004 (HT1080-MIC 3).

### Claim 33

An isolated cell line deposited at ECAAC under Accession 00122005 (HT1080-MIC 4).

### Claim 34

An isolated cell line deposited at ECAAC under Accession 00122006 (HT1080-MIC 5).

### Claim 35

An isolated cell line deposited at ECAAC under Accession 00122007 (HT1080-MIC 5a).

### Claim 36

An isolated cell line deposited at ECAAC under Accession 00122008 (HT1080-MIC 5b).

### Claim 37 (depends on 23)

The mini-chromosome generated by the method of claim 23, wherein the mini-chromosome is an NC-MiC.

### Claim 38 (depends on 23)

The mini-chromosome generated by the method of claim 23, wherein the mini-chromosome is a YAC.

### Claim 39 (depends on 23)

The mini-chromosome generated by the method of claim 23, wherein the mini-chromosome is a HAC.

### Claim 40 (depends on 23)

The mini-chromosome generated by the method of claim 23, wherein the mini-chromosome is a MAC.

### Claim 41 (depends on 23)

The mini-chromosome generated by the method of claim 23, wherein the mini-chromosome is a PLAC.

### Claim 42 (depends on 37, 38, 39, 40, 41)

A method of gene transfer comprising introducing into a target cell the mini-chromosome of any one of claims 37, 38, 39, 40 or 41.
